Target intelligence / Profile preview

ETS variant transcription factor 1 (ETV1)

Target
ETV1
Molecular classification
Transcription factor, DNA-binding protein
01

Overview

ETS variant transcription factor 1 (ETV1) is a member of the ETS family of transcription factors, which bind to specific DNA sequences and regulate the expression of genes involved in cell proliferation, differentiation, and migration[5]. ETV1 is frequently overexpressed or activated due to chromosomal translocations in several cancer types, notably aggressive prostate cancer, where it drives oncogenic gene programs including cell invasion and metastasis[1]. Its activity is modulated by signaling pathways such as mitogen-activated protein kinase (MAPK) and can be inhibited by TGF-β/SMAD pathway proteins, including direct binding with SMAD4, which represses its transcriptional activity[1]. As a transcription factor, ETV1 is not a classical receptor or enzyme, but a nuclear regulatory protein implicated in both normal developmental biology and tumorigenesis[5].

Other names
ER81Ets-related protein 81ETS translocation variant 1ets variant gene 1ets-related protein 81
02

Mechanism of action

Inhibitors block ETV1’s DNA-binding and transcriptional activation function[1]; also acts as partner for protein–protein interactions (e.g., with SMAD4)

03

Biological functions

Gene transcription regulationCell proliferationCell differentiationCell migrationInvasionOncogenic transformation
04

Disease associations

Cancer (notably prostate cancer, gastrointestinal stromal tumors, melanoma, Ewing sarcoma)Other (particularly relevant in neurodevelopment and certain non-malignant processes)
05

Safety considerations

Targeting a transcription factor may risk impacting normal gene regulation in development and tissue homeostasismay have off-target or pleiotropic effectslimited specificity for cancer vs. normal cells[1]
06

Interacting drugs

Small molecule inhibitors (one reported to suppress ETV1-driven proliferation in prostate cancer)

1 more in the full profile.

07

Biomarkers

ETV1 overexpression as prognostic biomarker in prostate cancer and other cancers[1]

Beyond the preview

Go deeper on ETS variant transcription factor 1 (ETV1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETS variant transcription factor 1 (ETV1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call